Global Rare Gastrointestinal Diseases Treatment Market Set To Expand To $2.47 Billion By 2030 At 12.4% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Rare Gastrointestinal Diseases Treatment Market During 2026–2030?
The rare gastrointestinal diseases treatment market size has demonstrated robust growth in recent years. It is anticipated to expand from $1.45 billion in 2025 to $1.53 billion in 2026, at a compound annual growth rate (CAGR) of 5.9%. Historically, this growth can be attributed to several factors, including the increasing recognition of rare GI disorders, the expansion of specialty gastroenterology centers, the availability of immunosuppressive and anti-inflammatory drugs, rising clinical research activity, and improved diagnostic accuracy.
The market for treating rare gastrointestinal diseases is projected to experience substantial expansion over the next few years. It is expected to reach $1.91 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This anticipated growth during the forecast period is driven by factors such as the increasing development of orphan drugs, rising investments in rare disease research, the growing adoption of biologic therapies, the expansion of precision medicine approaches, and increasing patient access to advanced treatments. Significant trends expected in this period include the increasing uptake of targeted biologic therapies, a rising focus on personalized treatment protocols, the growing use of advanced diagnostic devices, the expansion of enzyme replacement therapies, and enhanced integration of digital patient monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28317&type=smp
What Key Drivers Are Fueling The Growth Of The Rare Gastrointestinal Diseases Treatment Market?
The projected expansion of the rare gastrointestinal diseases treatment market is anticipated due to the increase in diagnostic testing. Diagnostic tests are medical procedures carried out to identify, confirm, or monitor illnesses, conditions, or infections in individuals. The heightened need for these tests primarily stems from greater understanding regarding the value of early disease detection, which facilitates prompt treatments and superior patient results. Such testing supports the treatment of rare gastrointestinal diseases by allowing for prompt and precise identification of underlying issues. It assists in pinpointing particular disease mechanisms, supports customized care plans, and enhances patient outcomes through early involvement. For instance, in December 2024, according to the National Health Service, a UK-based government department, the number of diagnostic tests by activity has reached 2,544,809 in 2024, an increase from 2,312,030 in 2023. Consequently, the uptick in diagnostic testing is fueling the growth of the rare gastrointestinal diseases treatment market.
Which Segment Classifications Are Used In The Rare Gastrointestinal Diseases Treatment Market Segment Analysis?
The rare gastrointestinal diseases treatment market covered in this report is segmented –
1) By Type: Drugs, Device
2) By Route Of Administration: Oral, Intravenous (IV) Or Injectable, Subcutaneous, Other Routes Of Administration
3) By Application: Eosinophilic Gastroenteritis, Hercksprung’s Disease, Chronic Intestinal Pseudo-Obstruction
4) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Drugs: Anti-Inflammatory Drugs, Immunosuppressive Agents, Biologic Therapies, Antibiotics, Proton Pump Inhibitors, Corticosteroids, Enzyme Replacement Therapies
2) By Devices: Endoscopic Devices, Diagnostic Imaging Systems, Surgical Instruments, Feeding Tubes, Stent Devices, Biopsy Devices
What Trends Are Affecting The Growth Of The Rare Gastrointestinal Diseases Treatment Market?
Leading firms within the rare gastrointestinal diseases treatment market are prioritizing the creation of advanced therapies, including fully human monoclonal antibodies, with the goal of addressing disease mechanisms and enhancing patient results. These fully human monoclonal antibodies are laboratory-developed antibodies, composed entirely of human proteins, designed to specifically identify and interact with molecules responsible for diseases. This action aids in precisely inhibiting or adjusting these molecules, thereby boosting treatment efficacy and minimizing adverse reactions. An example of this is the U.S. Food and Drug Administration (FDA) approval granted in August 2023 to Regeneron Pharmaceuticals Inc., a biotechnology company based in the US, for Veopoz (pozelimab-bbfg) to treat CHAPLE disease, which is a rare, life-threatening, and inherited gastrointestinal condition. Veopoz functions as a fully human monoclonal antibody specifically engineered to target complement factor C5. Its role is to help manage the overly active complement system implicated in protein loss and gastrointestinal harm observed in individuals with CHAPLE. This focused approach directly addresses the fundamental cause of the illness, thus averting severe symptoms and potential fatal complications.
Which Firms Are Contributing To The Rare Gastrointestinal Diseases Treatment Market Ecosystem?
Major companies operating in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., Ellodi Pharmaceuticals Inc.
Get The Full Rare Gastrointestinal Diseases Treatment Market Report:
Which Region Represents The Largest Share Of The Rare Gastrointestinal Diseases Treatment Market?
North America was the largest region in the rare gastrointestinal diseases treatment market in 2025. The regions covered in the rare gastrointestinal diseases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Rare Gastrointestinal Diseases Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Rare Gastrointestinal Diseases Treatment Market 2026, By The Business Research Company
Rare Diseases Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Gastrointestinal Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
